Nachrichten zur JOHNSON MATT. LS 1,101698 Aktie

This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy?

Johnson & Johnson is a picture of stability.…

The Zacks Analyst Blog Johnson & Johnson, Netflix, Arista Networks, Omega and AXIL

Johnson & Johnson leads Zacks latest Analyst Blog as new research highlights earnings beats, growth drivers, and risks across major…

Top Stock Reports for Johnson & Johnson, Netflix & Arista Networks

JNJs Q4 beat, Netflixs subscriber surge, and Arista Networks cloud demand highlight why these stocks headline todays top research reports.…

Morgan Stanley upgrades Johnson & Johnson, sees upside on robust drug pipeline

Morgan Stanleys price target implies that shares of Johnson & Johnson could rise another 17%.…

Johnson & Johnson Aktie: Neues Produktportfolio sorgt für Analysten-Upgrade!

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Morgan Stanley:Die Analysten von Morgan Stanley stufen die Aktie von Johnson &…

Johnson & Johnson Aktie: "Top Pick" im Segment der Large-Cap-Biopharmawerte

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Guggenheim Securities:Guggenheim-Analyst Vamil Divan habe das Kursziel für die Aktie von Johnson…

Johnson & Johnson Aktie: Solide Basis für langfristige Anleger

Frankfurt (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von XTB:Die Experten von XTB nehmen die Aktie der Johnson & Johnson (J&J) (ISIN:…

Johnson & Johnson Aktie: Überraschend starke Zahlen - Startet jetzt die nächste Rally?

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von TD Cowen:TD Cowen-Analyst Joshua Jennings habe das Kursziel für die Aktie von…

Johnson & Johnson Aktie: Starkes Setup - Kommt jetzt das nächste Top-Jahr für die Aktie?

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Goldman Sachs:Goldman-Sachs-Analyst Asad Haider habe das Kursziel für die Aktie von Johnson…

Johnson & Johnson Aktie: Zweistelliges Wachstum im Visier!

San Francisco (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Wells Fargo Advisors:Wells Fargo habe das Kursziel für die Aktie von Johnson…

Johnson & Johnson Aktie: Solide Q4-Zahlen - aber jetzt kommt der Bewertungs-Haken

Charlotte (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von BofA Securities:BofA-Analyst Jason Gerberry habe das Kursziel für die Aktie von Johnson &…

Johnson & Johnson Aktie: Q4-Überraschung und ein Plan für zweistelliges Wachstum!

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Morgan Stanley:Morgan-Stanley-Analyst Terence Flynn habe das Kursziel für die Aktie von Johnson…

Gewinn- sowie Umsatzwachstum bei Johnson & Johnson - Aktien von Netflix und Kraft Heinz unter Druck

Wien (www.aktiencheck.de) - Netflix gab um 2% nach, nachdem die Geschäftszahlen nicht in allen Punkten überzeugen konnten, so die Analysten…

This 2.4%-Yielding Dividend King Remains As Healthy As Ever

Johnson & Johnson had a strong year.…

MDAI: In the Blocks, Ready to Go upon Mid-Year Authorization

By John Vandermosten, CFANASDAQ:MDAIREAD THE FULL MDAI RESEARCH REPORTIt has now been approximately seven months since Spectral AI, Inc. (NASDAQ:MDAI)…

Johnson & Johnson (JNJ) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in…

Johnson & Johnson (JNJ) Tops Q4 Earnings and Revenue Estimates

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +1.05% and +1.84%, respectively, for the quarter ended December 2025.…

Market movers: Kraft Heinz, Lisata Therapeutics, Halliburton, Johnson & Johnson...

…

Johnson & Johnson Quartalszahlen Q4: Jahresprognose über Erwartungen

Wien (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse der Raiffeisen Bank International AG (RBI):Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI),…

AtaiBeckley seen as key beneficiary of Spravato’s strong growth: Jefferies

Jefferies analysts said the continued commercial momentum of Johnson & Johnson (NYSE:JNJ)s Spravato (esketamine nasal spray) could provide a meaningful...…

Johnson & Johnson forecasts 2026 profit above Wall Street estimates

Johnson & Johnson also reported a fourth-quarter profit ahead of expectations, buoyed by strong sales of the blood cancer therapy…

Johnson & Johnson reports Q4 earnings beat, issues 2026 guidance above forecasts

Johnson & Johnson (NYSE:JNJ) reported fourth quarter and full-year 2025 results that came in above market expectations and issued 2026…

U.S. judge allows experts to testify that talc products cause cancer in J&J cases

In a victory for thousands of women suing Johnson & Johnson over claims that the companys baby powder and…

Robotic surgery fuels Johnson & Johnson dividend growth outlook

Johnson & Johnson (JNJ) just made a move that investors have been waiting years to see. The healthcare heavyweight submitted…

Zacks Investment Ideas feature highlights: Netflix, Intel and Johnson & Johnson

Netflix, Intel and Johnson & Johnson headline Zacks Investment Ideas as key earnings reports approach amid steady estimates.…

Major Earnings Reports Streaming In: Global Week Ahead

The fourth-quarter U.S. earnings season heats up, with reports due from high-profile companies including Netflix (NFLX), Johnson & Johnson (JNJ),…

Tech Still Matters. But It’s a Good Thing More Stocks Are Rallying.

Stocks beyond tech are getting their day in the sun. Stocks like Morgan Stanley, Johnson & Johnson, and Caterpillar are…

Johnson & Johnson (JNJ) Beats Stock Market Upswing: What Investors Need to Know

Johnson & Johnson (JNJ) closed the most recent trading day at $209.72, moving +2.61% from the previous trading session.…

Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

…

Johnson & Johnson Aktie: Comeback für Healthcare 2026?

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Sanford C. Bernstein:Bernstein-Analyst Lee Hambright habe das Kursziel für die Aktie von…

Johnson & Johnson reaches deal with US government to lower drug prices

Johnson & Johnson said on Thursday it has reached a agreement with U.S. President Donald Trumps administration to cut drug…

Top Analyst Reports for Johnson & Johnson, Caterpillar and Qualcomm

JNJ is leaning on Innovative Medicine growth and MedTech momentum to offset the Stelara patent cliff as it heads into…

Covid-19: Bayer verklagt Biontech und Pfizer wegen Patenten für Impfstoffe

Der Pharmakonzern Bayer wirft Pfizer, Biontech und Moderna vor, bei ihren Covid-19-Impfstoffen eine patentierte mRNA-Technologie der Bayer-Tochter Monsanto genutzt zu…

Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $204.31, denoting a -1.47% move from…

Johnson & Johnson Aktie: Diese Medikamente könnten jetzt für den nächsten Schub sorgen!

London (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Barclays:Barclays habe das Kursziel für die Aktie von Johnson & Johnson (J&J) (ISIN:…

Apogee Therapeutics Aktie: J&J-Flop öffnet Tür für APG279

New York (www.aktiencheck.de) - Apogee Therapeutics-Aktienanalyse von BTIG:Die Analysten von BTIG haben das "buy"-Rating für die Aktie von Apogee Therapeutics…

Johnson & Johnson halts mid-stage trial of experimental eczema drug

Johnson & ?Johnson said ?it ?discontinued ?a ?mid-stage study of its experimental drug ?to treat atopic dermatitis, after it ?failed…

The Zacks Analyst Blog Highlights Invesco, Johnson & Johnson, NiSource, Bunge Global and Morgan Stanley

Invesco leads Zack list of five high-yield S&P 500 stocks, highlighting dividend strength and steady income potential for 2026.…

Johnson & Johnson pledges appeal following record $1.5 billion U.S. jury verdict in talc cancer case

…

Johnson & Johnson Aktie: RBC hebt Kursziel auf 240 USD - Wachstumschancen 2026!

Toronto (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von RBC Capital Markets:Die Analysten von RBC Capital Markets haben das Kursziel für die…

Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization

…

Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?

Based on the average brokerage recommendation (ABR), Johnson & Johnson (JNJ) should be added to ones portfolio. Wall Street analysts…

Johnson & Johnson Aktie: MedTech auf Wachstumskurs trotz Stelara-LOE - RBC hebt Kursziel an

Toronto (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von RBC Capital Markets:Die Analysten vom Investmenthaus RBC Capital Markets stufen die Aktie von…

Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial By Reuters

Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial…

These Institutional Investors Are Raising Their Stakes in Johnson & Johnson Stock. Should You Do the Same?

They might be on to something.…

Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, Johnson & Johnson (JNJ) closed at $210.01, indicating a +1.68% shift from the previous…

Johnson & Johnson Aktie: Medtech gilt als heimlicher Underperformer mit Turbo-Potenzial!

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse der Citigroup:Citi-Analystin Joanne Wuensch habe das Kursziel für die Aktie von Johnson &…

The Zacks Analyst Blog Highlights Broadcom, Exxon Mobil, Johnson & Johnson, Investors Title and Friedman Industries

AVGO draws attention as analysts spotlight its AI-driven momentum alongside notable updates on XOM, JNJ, ITIC and FRD.…

GSK Underweight

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK nach detaillierten Studiendaten von Johnson & Johnson…

Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note

The latest trading day saw Johnson & Johnson (JNJ) settling at $202.48, representing a -1.39% change from its previous close.…